NPRC/Institute
Nanogen Pharmaceutical Biotechnology Joint Stock Company; National Institute of Hygiene and Epidemiology (Hanoi, Vietnam)
Summary of Study
Nanocovax, a SARS-CoV-2 vaccine candidates based on recombinant protein production of the extracellular portion of the spike protein, was shown to be safe and effective in three animal models.
Year Published
2021
References
PMID: 34938290 / doi: 10.3389/fimmu.2021.766112
Contact Info
Min Si Do: minhsi@nanogenpharma.com
Keywords
SARS-CoV-2, protein subunit vaccine, Nanocovax, pathogenesis, mice, hamsters, primates
Coronavirus Investigated*
NHP Species
date entered
Study Type